SB 906: Permitting lawful prescription of crystalline polymorph psilocybin under FDA recommendations

Summary

The purpose of this bill is to permit lawful prescription, distribution, and marketing of any composition of crystalline polymorph psilocybin that the United States Food and Drug Administration approves and that is rescheduled by the United States Drug Enforcement Administration, in accordance with the recommendations of the United States Food and Drug Administration.

Latest recorded action

No action recorded yet.

Mar 14, 2026

This is the latest action supplied by the source, not the full legislative history.

Track bills like this one

Mandate alerts you when a bill that matters to your organization moves, and explains what it means.